Influence of clinical variables on the functional capacity of women undergoing chemotherapy

Elias, Thaís Cristina; Mendes, Lorena Campos; Soares, Maurícia Brochado Oliveira; Haas, Vanderlei José; Silva, Sueli Riul da

doi:10.5935/1414-8145.20150076

Acessibilidade / Reportar erro

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

RESEARCH • Esc. Anna Nery 19 (4) • Oct-Dec 2015 • https://doi.org/10.5935/1414-8145.20150076 copy

Influence of clinical variables on the functional capacity of women undergoing chemotherapy

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstract

Objective:

To evaluate how the chemotherapy protocol and tumor type influence the functional capacity of women diagnosed with gynecological cancer, breast cancer and gestational trophoblastic disease during chemotherapy.

Methods:

This was an observational and retrospective study with a quantitative approach and longitudinal design. The study included 438 women undergoing chemotherapy in a general hospital from January 2000 to December 2012.

Results:

The functional capacity of the study population had a mean score of 70 on the Karnofsky Performance Scale. A higher decline was noted in the functional capabilities of patients with gynecological cancer, and in women who used taxane chemotherapy protocols.

Conclusion:

It is germane to establish measures aimed at ensuring the prevention of side effects caused by chemotherapy, providing comprehensive and effective care for oncology patients.

Keyword:
Karnofsky Performance Status; Activities of Daily Living; Drug Therapy; Women's Health

Scores	N	Mean	Median	Standard deviation	Minimum	Maximum
Score corresponding to Cycle 1	438	78.22	80.00	11.482	30	100
Score corresponding to Cycle 2	438	78.11	80.00	9.980	30	100
Score corresponding to Cycle 3	438	77.67	80.00	9.642	40	100
Score corresponding to Cycle 4	390	77.28	80.00	9.556	40	100
Score corresponding to Cycle 5	339	77.02	80.00	9.372	40	100
Score corresponding to Cycle 6	316	76.09	80.00	9.008	40	100
Score corresponding to Cycle 7	57	75.26	80.00	11.512	40	90
Score corresponding to Cycle 8	45	75.78	80.00	11.380	40	90
Score corresponding to Cycle 9	21	75.71	80.00	13.256	40	90
Score corresponding to Cycle 10	14	73.57	80.00	12.774	40	90
Score corresponding to Cycle 11	8	76.25	80.00	11.877	50	90
Score corresponding to Cycle 12	4	77.50	80.00	5.000	70	80

Variable	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6
Cycle 1	_____	p = 0.63	p = 0.812	p = 0.211	p = 0.004	p ≤ 0.001
Cycle 2	p = 0.63	_____	p = 1.000	p = 1.000	p = 0.016	p ≤ 0.001
Cycle 3	p = 0.812	p = 1.000	_____	p = 1.000	p = 0.001	p ≤ 0.001
Cycle 4	p = 0.211	p = 1.000	p = 1.000	_____	p = 0.005	p ≤ 0.001
Cycle 5	p = 0.004	p = 0.016	p = 0.001	p = 0.005	_____	p ≤ 0.001
Cycle 6	p ≤ 0.001	p ≤ 0.001	p ≤ 0.001	p ≤ 0.001	p ≤ 0.001	_____

Variable	N	%	Mean (Karnofsky)
Chemotherapy protocol
Anthracyclines	206	47.03	81.29
Platinum	163	37.21	73.90
Taxanes	30	6.85	71.88
Others	39	8.9	82.39
Total	438	100	77.99
Tumor type
Breast cancer	224	51.14	81.38
Gynecological cancer	194	44.29	73.50
GTD	20	4.6	83.66
Total	438	100	77.99
Therapeutic modality
Exclusive chemotherapy	41	9.4	74.31
Chemotherapy associated with other therapies	397	90.63	78.38
Total	438	100	76.34
Mean scores of FC between the fourth and sixth chemotherapy cycle
Chemotherapy protocol
Anthracyclines	204	52.3	79.43
Platinum	125	32.05	72.36
Taxanes	28	7.18	72.02
Others	33	3.55	81.21
Total	390	100	76.78
Tumor type
Breast cancer	220	56.41	79.65
Gynecological cancer	153	39.23	71.77
GTD	17	4.36	84.70
Total	390	100	76.78
Therapeutic modality
Exclusively chemotherapy	34	9.4	74.07
Chemotherapy associated with other therapies	356	90.63	77.05
Total	390	100	75.56

	Variables	β	p
Mean scores of FC between the first and third chemotherapy cycles in relation to sociodemographic and clinical variables	Tumor type
	Breast cancer	-0.002	0.992
	Gynecological cancer	-3.382	0.028
	^* * Reference category. GTD	_____	_____
	Chemotherapy protocol
	Anthracyclines	-0.12	0.298
	Platinum	-0.102	0.462
	Taxanes	-0.146	0.049
	^* * Reference category. Others	_____	_____
	Therapeutic modality
	Exclusively chemotherapy	0.056	0.232
	^* * Reference category. Chemotherapy associated with other therapies	_____	_____
Mean scores of FC between the fourth and sixth chemotherapy cycles in relation to sociodemographic and clinical variables	Tumor type
	Breast cancer	-0.159	0.315
	Gynecological cancer	-0.732	<0.001
	^* * Reference category. GTD	_____	_____
	Chemotherapy protocol
	Anthracyclines	-0.093	0.437
	Platinum	0.112	0.439
	Taxanes	-0.037	0.627
	^* * Reference category. Others	_____	_____
	Therapeutic modality
	Exclusively chemotherapy	-0.081	0.232
	^* * Reference category. Chemotherapy associated with other therapies	_____	_____

Universidade Federal do Rio de Janeiro Rua Afonso Cavalcanti, 275, Cidade Nova, 20211-110 - Rio de Janeiro - RJ - Brasil, Tel: +55 21 3398-0952 e 3398-0941 - Rio de Janeiro - RJ - Brazil
E-mail: annaneryrevista@gmail.com

Acompanhe os números deste periódico no seu leitor de RSS

[1] Corresponding author: Sueli Riul da Silva. E-mail: sueliriul@terra.com.br